人类乙型肝炎病毒的M539V聚合酶变体对2'-脱氧-3'-硫代胞苷表现出耐药性，且合成病毒DNA的能力降低。
The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA.
作者信息
Ladner S K, Miller T J, King R W
机构信息
Avid Therapeutics, Inc., Philadelphia, Pennsylvania 19104, USA.
出版信息
Antimicrob Agents Chemother. 1998 Aug;42(8):2128-31. doi: 10.1128/AAC.42.8.2128.
Abstract
The cytosine analog 2'-deoxy-3'-thiacytidine (3TC) has been shown to be an effective treatment for chronic hepatitis B virus (HBV) infection. However, several liver transplant patients who were undergoing treatment with 3TC for HBV infection experienced a breakthrough of virus while on 3TC. The predominant virus found in these patients' sera contained either a valine or isoleucine for the methionine in the highly conserved YMDD nucleotide binding site in the HBV polymerase. To determine the biological relevance of the Met-to-Val substitution, we mutated a plasmid that contained a cDNA copy of the HBV pregenomic RNA such that when virus replication occurred during transient transfection of HepG2 cells, an M539V polymerase variant was produced. We found that in transiently transfected cells, this variant was approximately 330-fold less sensitive to the antiviral effects of 3TC and produced 7-fold less viral DNA than the wild type.
摘要
胞嘧啶类似物2'-脱氧-3'-硫代胞苷（3TC）已被证明是治疗慢性乙型肝炎病毒（HBV）感染的有效药物。然而，几名接受3TC治疗HBV感染的肝移植患者在使用3TC期间出现了病毒突破。在这些患者血清中发现的主要病毒在HBV聚合酶高度保守的YMDD核苷酸结合位点上，甲硫氨酸被缬氨酸或异亮氨酸取代。为了确定甲硫氨酸到缬氨酸替代的生物学相关性，我们对一个包含HBV前基因组RNA cDNA拷贝的质粒进行了突变，使得在HepG2细胞瞬时转染期间发生病毒复制时，产生M539V聚合酶变体。我们发现，在瞬时转染的细胞中，该变体对3TC抗病毒作用的敏感性比野生型低约330倍，产生的病毒DNA比野生型少7倍。
相似文献
1
The M539V polymerase variant of human hepatitis B virus demonstrates resistance to 2'-deoxy-3'-thiacytidine and a reduced ability to synthesize viral DNA.人类乙型肝炎病毒的M539V聚合酶变体对2'-脱氧-3'-硫代胞苷表现出耐药性，且合成病毒DNA的能力降低。
Antimicrob Agents Chemother. 1998 Aug;42(8):2128-31. doi: 10.1128/AAC.42.8.2128.
2
3
Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine.苯丙烯酰胺衍生物AT-61单独及与（-）β-L-2'，3'-二脱氧-3'-硫代胞苷联合使用对人乙型肝炎病毒复制的抑制作用
Antimicrob Agents Chemother. 1998 Dec;42(12):3179-86. doi: 10.1128/AAC.42.12.3179.
4
Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance.乙型肝炎病毒聚合酶YMDD基序外的其他突变在L(-)SddC（3TC）耐药中的作用
Biochem Pharmacol. 1998 May 15;55(10):1567-72. doi: 10.1016/s0006-2952(98)00050-1.
5
Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus.对乙型肝炎病毒拉米夫定耐药相关突变的功能分析
J Gen Virol. 1999 Mar;80 ( Pt 3):601-606. doi: 10.1099/0022-1317-80-3-601.
6
Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective.与3TC和泛昔洛韦使用相关的乙肝病毒突变体复制存在缺陷。
Hepatology. 1998 Feb;27(2):628-33. doi: 10.1002/hep.510270243.
7
Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.利用乙肝病毒重组杆状病毒-HepG2系统研究（-）-β-2'，3'-二脱氧-3'-硫代胞苷对乙肝病毒复制及共价闭合环状DNA积累的影响。
Antimicrob Agents Chemother. 1999 Aug;43(8):2017-26. doi: 10.1128/AAC.43.8.2017.
8
Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)--direct sequencing method for detecting lamivudine-resistant hepatitis B virus (HBV) variants with high sensitivity and specificity.肽核酸介导的聚合酶链反应钳夹技术（PMPC）的开发——用于高灵敏度和特异性检测拉米夫定耐药乙型肝炎病毒（HBV）变异体的直接测序方法
Rinsho Byori. 2003 Apr;51(4):313-9.
9
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.对拉米夫定耐药的乙型肝炎病毒突变的鉴定与特征分析。拉米夫定临床研究组。
Hepatology. 1998 Jun;27(6):1670-7. doi: 10.1002/hep.510270628.
10
Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants.拉米夫定耐药乙型肝炎病毒聚合酶基因变异的快速检测
J Virol Methods. 1999 Dec;83(1-2):181-7. doi: 10.1016/s0166-0934(99)00125-1.
引用本文的文献
1
Evaluation of single and combination therapies with tenofovir disoproxil fumarate and emtricitabine in vitro and in a robust mouse model supporting high levels of hepatitis B virus replication.评价富马酸替诺福韦二吡呋酯和恩曲他滨的单药和联合治疗在体外和在支持高水平乙型肝炎病毒复制的稳健小鼠模型中的效果。
Antimicrob Agents Chemother. 2012 Dec;56(12):6186-91. doi: 10.1128/AAC.01483-12. Epub 2012 Sep 17.
2
Randomized, double-blind study of emtricitabine (FTC) plus clevudine versus FTC alone in treatment of chronic hepatitis B.恩曲他滨（FTC）联合替比夫定与单用FTC治疗慢性乙型肝炎的随机双盲研究
Antimicrob Agents Chemother. 2006 May;50(5):1642-8. doi: 10.1128/AAC.50.5.1642-1648.2006.
3
Emergence of a novel mutation in the FLLA region of hepatitis B virus during lamivudine therapy.拉米夫定治疗期间乙型肝炎病毒FLLA区域出现新型突变。
Antimicrob Agents Chemother. 2005 Jul;49(7):2618-24. doi: 10.1128/AAC.49.7.2618-2624.2005.
4
Novel acyclic nucleoside phosphonate analogues with potent anti-hepatitis B virus activities.具有强效抗乙型肝炎病毒活性的新型无环核苷膦酸类似物。
Antimicrob Agents Chemother. 2005 Mar;49(3):1177-80. doi: 10.1128/AAC.49.3.1177-1180.2005.
5
Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening.用于抗病毒化合物筛选的表达拉米夫定耐药乙型肝炎病毒的稳定细胞系的构建
Antimicrob Agents Chemother. 2003 Jun;47(6):1936-42. doi: 10.1128/AAC.47.6.1936-1942.2003.
6
Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro.恩替卡韦对拉米夫定耐药乙型肝炎病毒复制及重组聚合酶的体外疗效。
Antimicrob Agents Chemother. 2002 Aug;46(8):2525-32. doi: 10.1128/AAC.46.8.2525-2532.2002.
7
Molecular, immunological and clinical properties of mutated hepatitis B viruses.乙型肝炎病毒变异体的分子、免疫学及临床特性
J Cell Mol Med. 2002 Jan-Mar;6(1):113-43. doi: 10.1111/j.1582-4934.2002.tb00317.x.
8
Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity.野生型和YMDD突变型乙型肝炎病毒聚合酶的动力学分析以及脱氧核苷酸浓度对聚合酶活性的影响。
Antimicrob Agents Chemother. 2002 Apr;46(4):1005-13. doi: 10.1128/AAC.46.4.1005-1013.2002.
9
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.使用编码乙型肝炎病毒耐药株的新型重组杆状病毒进行抗乙肝病毒化合物的交叉耐药性检测。
Antimicrob Agents Chemother. 2001 Jun;45(6):1705-13. doi: 10.1128/AAC.45.6.1705-1713.2001.
10
Development of resistance and perspectives for future therapies against hepatitis B infections: lessons to be learned from HIV.乙型肝炎感染耐药性的发展及未来治疗前景：从艾滋病病毒中吸取的教训
Infection. 1999;27 Suppl 2:S45-51. doi: 10.1007/BF02561672.
本文引用的文献
1
2
Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication.人乙型肝炎病毒（HBV）在稳定转染的肝癌细胞中的诱导表达：一种筛选HBV复制潜在抑制剂的新系统。
Antimicrob Agents Chemother. 1997 Aug;41(8):1715-20. doi: 10.1128/AAC.41.8.1715.
3
Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.原位肝移植后复发性感染时给予拉米夫定的乙肝病毒耐药性。
Lancet. 1997 Jan 4;349(9044):20-2. doi: 10.1016/S0140-6736(96)02266-0.
4
Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial.拉米夫定对中国乙肝表面抗原携带者的乙肝病毒DNA有抑制作用：一项安慰剂对照试验。
Hepatology. 1997 Jan;25(1):241-4. doi: 10.1002/hep.510250144.
5
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis.拉米夫定预防乙型肝炎肝硬化肝移植术后再感染
Lancet. 1996 Nov 2;348(9036):1212-5. doi: 10.1016/s0140-6736(96)04444-3.
6
Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo.乙肝病毒RNA依赖的DNA聚合酶突变在体内赋予对拉米夫定的耐药性。
Hepatology. 1996 Sep;24(3):714-7. doi: 10.1002/hep.510240340.
7
Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.在接受拉米夫定治疗的移植受者中，乙型肝炎病毒聚合酶突变的选择
Hepatology. 1996 Sep;24(3):711-3. doi: 10.1002/hep.510240339.
8
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.通过在浓度递增的2'，3'-二脱氧胞苷和2'，3'-二脱氧-3'-硫代胞苷中进行体外传代培养，产生1型人类免疫缺陷病毒的耐药变体。
Antimicrob Agents Chemother. 1993 Jan;37(1):130-3. doi: 10.1128/AAC.37.1.130.
9
Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription.人类乙型肝炎病毒ε序列的突变会影响RNA衣壳化和逆转录过程。
J Virol. 1995 May;69(5):3067-73. doi: 10.1128/JVI.69.5.3067-3073.1995.
10
Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.由于逆转录酶YMDD区域的突变，人免疫缺陷病毒1型对3'-硫代胞苷抑制剂产生快速体外抗性。
Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653-6. doi: 10.1073/pnas.90.12.5653.
Zotero 插件